Merck & Co., Inc. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
Merck & Co., Inc. (MRK) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2024-02-26
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2022-09-30 was $0.00.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2023 was $0.00.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2021 was $0.28, a 72.28% decline from fiscal 2020.
- Merck & Co., Inc. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2020 was $1.01, a 37.65% decline from fiscal 2019.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $0.28 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.30 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.13 10-Q · filed 2022-08-05 | $0.30 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $0.17 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.01 10-K · filed 2023-02-24 | |||
| 2020-09-30 | $0.24 10-Q · filed 2021-11-05 | $0.80 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $0.26 10-Q · filed 2021-08-09 | $0.56 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $1.62 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |